USANA Health Sciences, Inc. reiterated consolidated earnings guidance for the fiscal year 2022. The company reiterates fiscal 2022 net sales and diluted EPS outlook of $1.015 billion to $1.065 billion and $3.85 to $4.45, respectively.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
47.6 USD | +1.86% | +1.91% | -11.19% |
05-07 | DA Davidson Adjusts Price Target on USANA Health Sciences to $46 From $48, Maintains Neutral Rating | MT |
05-01 | Transcript : USANA Health Sciences, Inc., Q1 2024 Earnings Call, May 01, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-11.19% | 907M | |
+11.85% | 8.05B | |
+5.29% | 7.59B | |
+2.63% | 6.07B | |
-2.80% | 3.85B | |
-11.22% | 3.55B | |
-7.04% | 1.28B | |
-32.50% | 1.03B | |
+12.52% | 971M | |
-15.69% | 813M |
- Stock Market
- Equities
- USNA Stock
- News USANA Health Sciences, Inc.
- USANA Health Sciences, Inc. Reiterates Consolidated Earnings Guidance for the Fiscal Year 2022